Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti ‐PLA2R positive primary membranous nephropathy

Journal of Clinical Apheresis, EarlyView.

Source: Journal of Clinical Apheresis - November 2, 2017 Category: Hematology Source Type: research